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ARTICLE OPEN
Identifying cases of undiagnosed, clinically significant
COPD in primary care: qualitative insight from patients
in the target population
Nancy K Leidy1, Katherine Kim1, Elizabeth D Bacci1, Barbara P Yawn2, David M Mannino3, Byron M Thomashow4, R Graham Barr4,
Stephen I Rennard5, Julia F Houfek5, Meilan K Han6, Catherine A Meldrum6, Barry J Make7, Russ P Bowler7, Anna W Steenrod1,
Lindsey T Murray1, John W Walsh8 and Fernando Martinez9, for the High-Risk-COPD Screening Study Group10
BACKGROUND: Many cases of chronic obstructive pulmonary disease (COPD) are diagnosed only after significant loss of lung
function or during exacerbations.
AIMS: This study is part of a multi-method approach to develop a new screening instrument for identifying undiagnosed, clinically
significant COPD in primary care.
METHODS: Subjects with varied histories of COPD diagnosis, risk factors and history of exacerbations were recruited through five
US clinics (four pulmonary, one primary care). Phase I: Eight focus groups and six telephone interviews were conducted to elicit
descriptions of risk factors for COPD, recent or historical acute respiratory events, and symptoms to inform the development of
candidate items for the new questionnaire. Phase II: A new cohort of subjects participated in cognitive interviews to assess and
modify candidate items. Two peak expiratory flow (PEF) devices (electronic, manual) were assessed for use in screening.
RESULTS: Of 77 subjects, 50 participated in Phase I and 27 in Phase II. Six themes informed item development: exposure (smoking,
second-hand smoke); health history (family history of lung problems, recurrent chest infections); recent history of respiratory events
(clinic visits, hospitalisations); symptoms (respiratory, non-respiratory); impact (activity limitations); and attribution (age, obesity).
PEF devices were rated easy to use; electronic values were significantly higher than manual (Po0.0001). Revisions were made to
the draft items on the basis of cognitive interviews.
CONCLUSIONS: Forty-eight candidate items are ready for quantitative testing to select the best, smallest set of questions that,
together with PEF, can efficiently identify patients in need of diagnostic evaluation for clinically significant COPD.
npj Primary Care Respiratory Medicine (2015) 25, 15024; doi:10.1038/npjpcrm.2015.24; published online 16 April 2015
INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is one of the most
common lung conditions seen in clinical practice and the fourth
leading cause of death worldwide.1 Internationally, data suggest
that only a fraction of those with COPD (9 to 22%) have been
diagnosed.2 In the United States, analyses of data from the Third
National Health and Nutrition Examination Survey (NHANES
2007–2010) found that fewer than 50% of adults with airflow
obstruction have been told they have COPD.3
Goals of COPD management include relieving symptoms,
improving exercise capacity and reducing the risk of acute
exacerbations of COPD.4–6 Long-acting inhaled therapies, supple-
mental oxygen and pulmonary rehabilitation are particularly
beneficial to symptomatic patients and to those with a forced
expiratory volume in one second (FEV1) less than 60% predicted.
6
Exacerbations are common and costly events associated with decline
in lung function,7–9 impaired health-related quality of life10,11 and
death.12 A history of acute exacerbations of COPD represents the
most important risk factor for subsequent events,13 with treatments
available to decrease frequency and improve outcomes.4,12
There is evidence suggesting that many patients are first
diagnosed with COPD when their airway obstruction has
progressed substantially or during an acute respiratory
illness.14–19 Studies in primary care suggest that the proportion
of newly diagnosed COPD patients with moderate-to-severe
airway obstruction in primary care ranges from 43% (Scotland,
Colorado)15 to 70% (Greece).16 A United States managed care
database analysis suggested that 31% were GOLD III or IV,17
whereas a study in China found that 86% were moderate to severe
and 34% had ⩾ 2 exacerbations the prior year.18 Exacerbation
history is further exemplified by a study in France where
investigators found that 96% of patients with newly diagnosed
chronic bronchitis had been treated with antibiotics for similar
episodes in the past year and 41% had at least two such
episodes.19 Identifying individuals with undiagnosed clinically
significant COPD (FEV1 o60% predicted or exacerbation risk)
should set in motion effective medical treatment and improve
short- and long-term health outcomes.
Several instruments have been proposed for COPD case
identification, defined by airflow limitation (FEV1/FVC (forced vital
capacity) o0.70) without reference to exacerbation risk.20–32
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Methods used to develop these instruments vary widely. Target
and test populations range from those with a history of
cigarette smoking only21,25,29 to populations of smokers and
non-smokers,20,22,26,27,30,32 and settings that include primary
care, specialty clinics20–22,26,28,30 and general population
screening.25,29,32 A few of these development studies have utilised
qualitative research methods to inform and refine instrument
structure and content22,27,28 or tested the use of peak expiratory
flow (PEF) along with a questionnaire to enhance precision.29–32
A 2008 National Institutes of Health (NIH)-COPD Foundation
workshop suggested a three-stage approach for identifying
undiagnosed individuals with moderate-to-severe airflow obstruc-
tion (FEV1 o60%): a questionnaire to eliminate those unlikely to
have severe disease, a simple measure of expiratory airflow to
exclude those with normal or near-normal pulmonary function,
and diagnostic evaluation, including clinical assessment and
spirometry.33 Nelson et al.32 tested the effectiveness of this
approach, by screening 5,638 diagnosed and undiagnosed
individuals from the general population attending public events.
In this setting, 6.3% of 3,791 with ⩾ 2 risk factors had abnormal
PEF, suggesting that a more sensitive questionnaire is needed.
We are developing a new screening method for identifying
cases of clinically significant COPD (FEV1 o60% and/or at risk for
acute exacerbations of COPD) in primary care settings. The two-
step process will include a questionnaire and pre-bronchodilator
peak flow (PEF) to identify patients in need of further diagnostic
evaluation. PEF will be measured using a familiar, inexpensive and
widely available device for estimating the presence of airflow
obstruction.31–33 Development methods for the questionnaire
included a review of the literature,34 analyses of three existing
COPD data sets using random forests methodology35 and
qualitative research with individuals from the target population.
This paper presents the qualitative research used to inform
thematic content, format, instructions and candidate items for the
screening questionnaire. The intent was to develop a compre-
hensive pool of items for empirical testing, maximising content
validity by using words and phrases easily understood by men and
women in the target population. Ease of use and equivalence of
two PEF metres were also assessed.
MATERIALS AND METHODS
Study design
This was a two-phase qualitative study: Phase I (elicitation) included focus
groups and interviews, and Phase II involved cognitive interviews (see
Online Supplementary).
Sample
The Phase I sample included participants from one of four categories (see
Table 1). COPD severity was based on airflow obstruction, defined by the
Global Initiative for Chronic Obstructive Lung Disease (GOLD),36 and risk
factors based on the literature and data mining. Subjects in categories
(groups) 1 and 2 provided information on symptoms, risk factors, history
and other breathing-related issues from the perspective of people recently
diagnosed with clinically significant COPD—the target population. Groups
3 and 4 were designed to provide insight into how experienced (risk factor)
but non-COPD (diagnosis naive) subjects describe their respiratory
symptoms, risk factors, history and other breathing-related issues.
Inclusion criteria were as follows: ⩾ 40 years old; stable state spirometry
(FEV1, FEV1% predicted, FEV1/FVC) in the past 12 months (on file or willing
to undergo spirometry at the time of data collection); and able to attend a
focus group or telephone interview, read and speak English and to provide
written informed consent. Individuals were not eligible if they had physical
or psychological impairments precluding participation or were hospitalised
for a respiratory infection within the past 30 days. Current smokers
(⩾10 pack-years), ex-smokers (history of ⩾ 10 pack-years) and never
smokers (⩽100 cigarettes/pipes/cigars in a lifetime) were included.
Procedures
Participants were recruited from four pulmonary clinics and one primary
care clinic in the United States. Convenience sampling was used; clinical
members of the Study Group approached potential participants by phone
or during clinic visits. Efforts were made to recruit a diverse sample in
terms of age, smoking status and history, gender, race/ethnicity and
educational level. The protocol was approved by a central Institutional
Review Board and local Institutional Review Board at each site; written
informed consent was obtained from all the participants.
Focus groups and interviews
Focus groups were held in a private room in the clinic; interviews were
conducted by telephone. Experienced, trained research staff used a semi-
structured interview guide to facilitate discussion. The guide included
open-ended questions asking participants to describe their breathing-
related symptoms and COPD risk-related experiences; COPD patients were
also asked to consider these issues relative to their recent diagnosis.
Sample questions for the COPD Groups (1 and 2) included the following:
‘Looking back, were there any ‘signals’ that suggested you might have a
breathing condition?’ and ‘What symptoms or experiences did you have
that led you to believe you might have a breathing problem?’ Sample
questions for those without COPD (3 and 4) included the following:
‘Describe your breathing for us. Are there any other symptoms you
associate with your breathing?’ and ‘Can you think of any other
experiences related to the symptoms we just discussed?’
Two researchers were present during focus groups: one served as
moderator (LTM), while the second observed and took field notes (KK or
AWS). Groups lasted 1.5–2 h, with breaks taken as needed. Telephone
interviews were 1:1 (LTM, KK or AWS), with the interviewer taking notes,
and they lasted for 20–50min. Focus groups and interviews were
audio-recorded and transcribed verbatim, with the data cleaned and
de-identified for analyses.
Peak expiratory flow
Following each focus group or interview, clinical staff performed PEF on
each participant using electronic (Vitalograph Asma-1 USB, Lenexa, KS,
USA) and manual (Vitalograph AsmaPlan mech PFM) devices. Order of
administration was randomised; SafeTway disposable mouthpieces were
used. Upon completion, participants and staff completed ease-of-use
Table 1. Sample diagnostic and risk status classification (N= 50)
Group Subgroup Description Number (N)
COPD, recently
diagnosed
Group 1 COPD—GOLD IIa 7
Diagnosed ⩽ 6 months
No history of respiratory
events in the past yearb
Group 2 COPD—GOLD II–IVa 13
⩾ 1 respiratory event in
the past yeara
Diagnosed ⩽ 6 months
At-risk, no COPD Group 3 2–3 risk factorsc 20
No COPD diagnosis
Group 4 ⩾4 risk factorsc 10
No COPD diagnosis
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced
expiratory volume in one second; GOLD, Global Initiative for Chronic
Obstructive Lung Disease.
aGOLD Stage II (FEV1% predicted 50–80%), Stages II–IV (FEV1% predicted
o50%), pre-bronchodilator.
bRespiratory event defined by colds, upper respiratory infection, missed
work, clinic visit/ER visit/hospitalisation.
cSymptoms (shortness of breath with activity; cough; phlegm (sputum) in
the absence of a cold, wheezing); exposure (cigarette smoking; second-
hand tobacco or other kinds of smoke at home or work; dust, gases or dirty
air at work); health history (asthma; serious childhood breathing
conditions; colds settling in the chest); recent history (⩾1 respiratory
event in the past year with missed work; clinic or emergency room visit or
hospitalisation).
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ratings (very easy, easy, neither difficult nor easy, difficult or very difficult
to use).
Demographic and clinical measures
Participants also completed a sociodemographic and clinical history form,
the RAND 36-Item Short Form Health Survey (SF-36)37 and the COPD
Assessment Tool,38 a 10- to 15 -min activity following the focus group or
interview. Spirometric values (FEV1, FEV1% predicted, FEV1/FVC) were
obtained for all subjects, either from clinical charts (COPD groups) or by
clinical site staff, at the time of the focus group or interview (no
bronchodilation).
Data analysis
Using a content analysis approach, data (transcripts) were examined for
key themes and constructs. A coding dictionary was developed and ATLAS.
ti (version 7.1) was used to organise data. Two analysts independently
coded the first transcript, and codes were compared and reconciled with
senior scientific oversight. Terms and definitions in the coding dictionary
were then refined for clarity. The remaining transcripts were coded
thematically by one analyst and reviewed by a second analyst, with
discrepancies resolved through discussion with the senior analyst.
Saturation was defined by consistency of themes, construct descriptions
or terms across groups and interviews.
Descriptive statistics were used to summarise sample characteristics, PEF
values and PEF ease of use. A two-way analysis of variance was used to
determine whether there was a significant difference between electronic
and manual PEF values for participants with and without COPD. Paired-
sample t-tests were used to compare PEF values between the electronic
and manual devices within groups.
Item pool development and cognitive interviewing
Results were examined together with those from the literature review34
and data mining35 to inform the development of a pool of candidate
questions for further evaluation and testing. Items were generated using
an iterative process of development, review, revision, discussion and
revision, with input from the High-Risk-COPD Screening Study Group.
Candidate questions with instructions were formatted in a questionnaire
layout and evaluated by a new set of subjects from the target population
using cognitive interviewing methodology (see Online Supplementary).
RESULTS
Eight focus groups (n= 44) and six one-on-one telephone
interviews (n= 6) were conducted. Sample characteristics are
summarised in Tables 2 and 3. For the COPD patients, mean
post-bronchodilator FEV1 was 68% predicted (s.d. = 10) (mean
FEV1 = 2.2 l (s.d. = 0.8)), and time since diagnosis averaged
three months.
Spirometric values for three cases in the non-COPD groups
suggested possible airway obstruction; these participants were
referred to their physician for follow-up. In two cases, spirometry
was performed after their focus groups. The third case was
uncovered after screening and enrolment, and the decision was
made to have him participate in the originally assigned no-COPD
group so that he could share his experiences in an environment of
people without COPD experience. Data from these three cases
were also examined separately, comparing their responses with
others.
Six major themes were identified in the data: (1) exposure to
smoke and other pollutants (e.g., chemicals, paint, gasoline), either
through a friend/relative, work environment or living condition;
(2) personal and family history of respiratory health conditions,
such as emphysema, pneumonia, frequent colds and sinus
infections; (3) recent history of respiratory events, including
factors that may trigger an event (perfumes, cigarette smoke,
exertion) and recent clinic visits or hospitalisations owing to
respiratory symptoms such as shortness of breath, coughing and
chest tightness that continued to worsen; (4) symptoms, including
respiratory (e.g., shortness of breath with and without exertion,
sputum and phlegm production, wheezing, chest tightness and
congestion) and nonrespiratory (e.g., feeling tired after slight
Table 2. Sample demographic characteristics
Characteristic Total (N= 50) COPD (Groups 1 & 2) (N=20) Risk, no COPD (Groups 3 & 4) (N= 30)
Age, Mean (s.d.) 60 (12) 62 (14) 58 (11)
Gender, n (%) Male 24 (48%) 7 (35%) 17 (57%)
Ethnicity, n (%)
Hispanic or Latino 4/48 (8%) 2 (10%) 2/28 (7%)
Not Hispanic or Latino 44/48 (92%) 18 (90%) 26/28 (93%)
Racial background, n (%)a
White 36 (72%) 17 (85%) 19 (63%)
Black or African American 13 (26%) 2 (10%) 11 (37%)
American Indian or Alaska Native 1 (2%) 1 (5%) 0 (0%)
Marital status, n (%)
Married 16 (32%) 8 (40%) 8 (27%)
Other (single, divorced, separated, widowed) 34 (68%) 12 (60%) 22 (73%)
Employment status, n (%)a
Employed 17 (34%) 6 (30%) 11 (37%)
Retired 13 (26%) 8 (40%) 5 (17%)
Disabled 14 (28%) 6 (30%) 8 (27%)
Other (student, unemployed, other) 9 (18%) 3 (15%) 6 (20%)
Education level, n (%)
High school or less 16 (32%) 8 (40%) 8 (27%)
Some college, vocational training 22 (44%) 6 (30%) 16 (53%)
College degree or more 12 (24%) 6 (30%) 6 (20%)
Abbreviation: COPD, chronic obstructive pulmonary disease.
aCategories are not mutually exclusive.
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exertion, low energy, sleeping problems such as waking up at
night feeling short of breath); (5) impact of breathing-related
problems on daily life (e.g., slowing down or stopping owing to
breathlessness, unable to complete daily chores, unable to keep
up with others); and (6) the attribution of symptoms or
experiences (e.g., breathless, being tired or slowing down
attributed to age or weight; cough attributed to smoking or
smoke exposure).
Themes were consistent across COPD and non-COPD partici-
pants, with some cross-group variation in emphasis within each
theme. Spontaneous symptom reporting rates were generally
lowest for Group 3 (non-COPD ⩽ 2 risk factors); rates for Group 4
(non-COPD, ⩾ 4 risk factors) were similar to the COPD groups on
sputum/phlegm (100%); tight, wheezy or noisy chest (90%);
slowing down (40%); fatigue (50%); and sleep problems (40%). No
qualitative differences were found between data provided by the
three subjects with evidence of airway obstruction and other
participants. Sample quotes for each theme are shown in Table 4.
Candidate item content is shown in Table 5.
Electronic and manual PEF devices were rated as ‘easy’ or ‘very
easy’ to use by participants (96%; 94%) and clinical site staff (80%;
84%). PEF values by device and group are shown in Table 6.
With the data analysed, a draft questionnaire with 48 candidate
items was constructed and subjected to cognitive interviewing in
a separate sample of 27 subjects. The instructions and item pool
were easily understood and appropriately interpreted by the
Table 3. Sample clinical characteristics
Characteristic Total (N= 50) COPD (Groups 1 & 2) (N=20) Risk, no COPD (Groups 3 & 4) (N= 30)
Smoking status and history
Never smoked, n (%) 17 (34%) 3 (15%) 14 (47%)
Smoked cigarettes, n (%) 32 (64%) 17 (85%) 15 (50%)
Former, n (%) 16/32 (50%) 6/17 (35%) 10/15 (67%)
Current, n (%) 16/32 (50%) 11/17 (65%) 5/15 (33%)
Age started smoking, mean (s.d.) 17 (4) 17 (5) 17 (4)
Duration of smoking (years) 33 (13) 37 (10) 29 (14)
Pack-yearsa 40 (32) 44 (34) 34 (30)
Other risk factors, n (%) Yes
History of asthma 20 (40%) 9 (45%) 11 (37%)
Exposure (smoke, dust, gas, air) 41 (82%) 18 (90%) 23 (77%)
Colds move to chest 35 (70%) 16 (80%) 19 (63%)
Childhood breathing conditions 7/49 (14%) 3/19 (16%) 4 (13%)
Family history of breathing problems 22 (44%) 9 (45%) 13 (43%)
Breathing-related symptomsb, n (%)
None 3 (6%) 1 (5%) 2 (7%)
Chest symptomsc 26 (52%) 13 (65%) 13 (42%)
Cough 28 (56%) 15 (75%) 13 (43%)
Shortness of breath (overall) 42 (84%) 16 (80%) 26 (87%)
With strenuous activity 38 (76%) 15 (75%) 23 (77%)
With light activity 25 (50%) 13 (65%) 12 (40%)
At rest 9 (18%) 5 (25%) 4 (13%)
Breathing events past year, n (%)
None 18 (36%) 3 (15%) 15 (50%)
Cold 18 (36%) 13 (65%) 5 (17%)
Chest infection or pneumonia 16 (32%) 10 (50%) 6 (20%)
Breathing event impact, n (%)
Missed work or school 9 (18%) 5 (25%) 4 (13%)
Clinic visit 15 (30%) 5 (25%) 10 (33%)
Emergency room visit/urgent care 10 (20%) 6 (30%) 4 (13%)
Hospitalisation 3 (6%) 2 (10%) 1 (3%)
Non-respiratory health conditions, n (%)
None 7 (14%) 0 (0%) 7 (23%)
Cardiovascular 20 (40%) 8 (40%) 12 (40%)
Metabolic 7 (14%) 0 (0%) 7 (23%)
Musculoskeletal 14 (28%) 9 (45%) 5 (17%)
Other (e.g., GI, cancer) 17 (34%) 5 (25%) 12 (40%)
Health status, mean (s.d.), median
SF-36—Physical Component Summary (PCS) 38 (12); 37 36 (13)d; 37 39 (12)d; 37
SF-36—Mental Component Summary (MCS) 47 (13); 50 46 (11)e; 46 47 (14)e; 51
COPD Assessment Test (CAT) 17 (9); 18 19 (9)f; 19 16 (8)f; 17
Abbreviations: COPD, chronic obstructive pulmonary disease; GI, gastrointestinal; NS, not significant.
aPack-years= (cigarettes per day/20 cigarettes per pack) × duration of smoking (years).
bCategories are not mutually exclusive.
cChest congestion, discomfort, tightness, pain or wheeze.
dScale: 0–100; higher scores are better; t= 0.91: COPD versus non-COPD, NS, P= 0.37.
eScale: 0–100; higher scores are better t= 0.28: COPD versus non-COPD, NS, P= 0.78.
fScale: 0–100; higher scores are worse t= 1.49: COPD versus non-COPD, NS, P= 1.4.
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Table 4. Key themes and representative quotesa
Exposure:
J All my family smokes. 3: 004-102
J I worked in a tobacco warehouse for about a year…I was a…dancer for 13 years, barroom smoke. 2: 002-110
J Working with material, fuzzy material and breathing it in. 2: 001-101
J Around different chemicals, paint, plastic, you name it and we did it all. 1: 002-101
Personal and family history:
J My parents were both smokers…my mother was 92 when she was diagnosed with COPD and my father died of emphysema. 2: 001-139
J When it takes that long to recover from 1, when you have like 2 or 3 in the course of a 3 or 4-month winter…it ends up you’re feeling—you’re feeling
crummy for 75% of the time. 1: 001-145
J I’ve gotten sinus infections in the spring and the fall, I bet, for the last 10 years…and I think like 5 times it has ended up as pneumonia. 2: 006-104; I’ve had
pneumonia … maybe 7, 8 times in my life. 3: 004-125
Recent history:
J The smell of—of detergents and, uh, lovely perfumes do affect, um, my deep breathing. 2: 001-123
J If I’m going to be around dust or chemicals or cigarette smoke…I have to wear a mask because if not, it will be like, uh, I will, uh, start feeling the
tightness in midst of—at first sign, it’s like my chest will start tightening up. 3: 004-127
J You’re trying to breathe and it hurts, and it hurts and you have pain and then it hurts and …then go to the hospital for it—it’s the lungs. 4: 003-131
Symptoms—respiratory and non-respiratory:
J Just feels like you've got like something like a ton of bricks just sitting on your chest. 2: 002-110
J I wouldn't have any trouble breathing hardly, but I'd just be running short on breath. Like I could walk a country mile, like a stroll, but I can't go up a flight
of stairs if I get in a hurry. 1: 002-103
J I walk up the driveway to my car, and--I'm really tired after that. I feel me [panting] breathing…you kind of feel tired all the time. 2: 002-106
Impact:
J I’d go out to lunch with…people from my office… I’d really have to kind of push myself to keep up with them ….had to work to keep up. 2: 001-141
J I have a hard time…climbing stairs, and I've got to take it slow. I have to walk slowly. 1: 002-113
J Walk up and down them halls, and sometimes I just feel like okay, wait, and I stop for a minute. 4: 002-113
Attribution:
J I've got a smoker's cough because I smoke. 2: 002-109
J I noticed I was starting to slow down with my breathing, but it actually got worse after I started having all this other health issues. 1: 002-101
Abbreviation: COPD, chronic obstructive pulmonary disease.
aSuperscripts show subgroup membership and patient ID.
Table 5. Key themes and candidate content
Theme Candidate content
Exposure ● Smoking (current, history)
● Second-hand smoke
● ‘Dirty’ air
Personal and family history ● Family smoking history
● Relatives with COPD, lung cancer, asthma
● Personal history of recurrent chest infections/colds
Recent history ● Environmental triggers affect breathing
● Colds, acute bronchitis
● Clinic visits for or with breathing-related problems
● Hospitalisations for or with breathing-related problems
● Missed school or work days owing to breathing-related problems
Symptoms ● Respiratory: dyspnoea, cough, sputum, chest congestion, wheezy/noisy breathing, chest tightness, chest heavy
● Non-respiratory: fatigue, feeling tired, lack of energy, sleep difficulties, slowing down
Impact ● Activity limitations—stairs, steps, walking quickly
● Frequent stopping, keeping up with others
Attribution ● Symptom attribution to smoking, age, weight or other health conditions
Abbreviation: COPD, chronic obstructive pulmonary disease.
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subjects; several adjustments were made to enhance clarity. PEF
results were similar to those found in the elicitation sample (see
Online Supplementary).
DISCUSSION
Main findings
This qualitative study is part of a larger multi-method approach to
develop a screening method for identifying patients with
undiagnosed, clinically significant COPD in primary care. Six key
themes were identified; candidate items were developed, using
words and phrases easily understood by people in the target
population. Although participants and clinical staff rated the two
PEF devices easy to use, values produced by the electronic device
were significantly higher than those provided by the manual
device.
Strengths and limitations of this study
This is among the first known uses of qualitative data to inform
the development of a screening tool for COPD case identification
in a clinical setting. The study included men and women with
varied COPD experiences, risk factors and education. The fact that
all subjects were from the United States and most were white
(70%) and not Hispanic or Latino (92%) is a limitation of the study.
In addition, although a larger number of subjects with undiag-
nosed COPD would have been ideal, a study design that explicitly
included screening and identifying subjects with undiagnosed
clinically significant COPD (using methods not designed for this
purpose) would have been cost-prohibitive. The fact that all
moderators and interviewers were female may have influenced
participant responses, although staff were experienced and
trained to encourage discussion and minimise bias.
Interpretation of findings in relation to previously published work
The attribution theme offers insight into why certain symptoms
are not reported or recognised as indicators of COPD. Participants
who smoked often attributed their cough to smoking; others
attributed slowing down, feeling tired or becoming breathless
with exertion to ageing, weight or other health issues. These
findings are consistent with descriptions of barriers to diagnosis;39
quantitative evidence that symptom-based diagnosis of COPD in
primary care settings is unreliable, particularly if patients are
overweight;40 and qualitative research suggesting that people
minimise and negotiate the importance of symptoms and need to
acknowledge ‘there must be something wrong’ as part of the
diagnostic process.41
Most of the respiratory symptoms identified in this study were
consistent with existing, symptom-based questionnaires for
identifying undiagnosed COPD. Cough, phlegm, dyspnoea and
wheeze,21–23 as well as history of chest infections, breathing-
related disability or hospitalisations,23,24 for example, were
broached and characterised by these participants. In addition,
however, subjects described chest symptoms, including conges-
tion, noisy or tight, as well as feelings of fatigue and sleep
difficulties. Participant descriptions of family history of respiratory-
related problems, symptoms, activity limitations and acute
respiratory illnesses offer new insight into candidate items for
identifying undiagnosed cases of clinically significant COPD.
Smokers and non-smokers were included to facilitate the use of
the questionnaire in both groups. There is evidence to suggest
that one-fourth to one-third of all COPD cases are non-smokers,
with country-to-country variability.42 The international study of
Lamprecht et al.42 found that 81% of never smokers with
moderate-to-severe airway obstruction were undiagnosed. The
study of Bednarek et al.2 in Poland suggested that detection of
COPD is reduced by 26% when a ‘smokers only’ criterion is used,
whereas in the Third US NHANES database, ‘never smokers’
accounted for 23% of airway obstruction cases, 69% of whom had
no prior respiratory diagnosis.43
Sample clinical characteristics provide further qualitative insight
into the challenges associated with variable selection for case
identification. Descriptively, the frequency of breathing-related
symptoms (e.g., cough, shortness of breath) and other risk factors
(e.g., history of asthma, family history of breathing problems) were
similar across groups. The COPD group reported more breathing
events over the past year (e.g., cold, chest infection). Although
there were no significant differences in health status between the
two groups, the descriptively higher COPD Assessment Test scores
for COPD subjects suggest a trend toward poorer health in areas
specific to COPD, with the mean between-group difference
exceeding the proposed two-point minimum clinically important
difference.44 These exploratory results suggest that a small set of
targeted questions may be more effective than a large number of
general health questions for identifying people with COPD.
Implications for future research, policy and practice
As part of our screening tool development, we will be testing the
added value of including PEF to increase sensitivity and specificity.
To facilitate and optimise utilisation of PEF as part of the screening
process, we evaluated the usability and comparability of electronic
and manual devices. Most patients and clinic staff rated the
devices easy or very easy to use, suggesting that either might be
suitable. However, differences in PEF values indicate a need for
standardisation to simplify the process by providing a single
threshold for interpretation. With cost and availability in mind, the
manual PEF device will be tested further during the next phase of
screening tool development. The questionnaire’s sensitivity and
specificity will be optimised independently of PEF, and thus those
preferring to use FEV1 or PEF captured through an electronic/
digital device would be free to do so, applying their preferred
threshold for follow-up evaluation.
Conclusions
This qualitative study is part of a multi-method approach for
developing a new screening method for identifying primary care
patients who may have undiagnosed, clinically significant COPD.
Six themes were identified: exposure, personal and family health,
recent history of respiratory events, respiratory and non-
respiratory symptoms, impact, and attribution. A pool of 48
candidate items was developed and revised based on cognitive
interview results. Items will be tested and eliminated during the
next phase of instrument development, with the intent of finding
the best, smallest set of questions that, together with PEF, can
identify patients in need of diagnostic evaluation for COPD.
Table 6. Mean (s.d.) peak flow by device type and group
Device Total (N= 50) COPD
(Groups 1 & 2)
(N=20)
Risk, no COPD
(Groups 3 & 4)
(N=30)
Electronic 362 (158) 274 (124) 424 (151)
Manual 315 (131) 249 (104) 358 (130)
Difference 43.79 (60.76) 24.89 (38.69)a 57.09 (70.05)a
t= 4.89b t= 2.80c t = 4.23d
Abbreviation: ANOVA, analysis of variance; COPD, chronic obstructive
pulmonary disease.
aANOVA testing group effects showed no difference (F= 3.29, P= 0.076).
bPaired t-test, Po0.0001.
cPaired t-test, Po0.05.
dPaired t-test, Po0.001.
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